Hannah Alsdurf1, Philip C Hill2, Alberto Matteelli3, Haileyesus Getahun4, Dick Menzies5. 1. Montreal Chest Institute, McGill University, Montreal, QC, Canada. 2. Centre for International Health, University of Otago, Dunedin, New Zealand. 3. Global TB Programme, WHO, Geneva, Switzerland; Clinic of Infectious and Tropical Diseases, WHO Collaborating Center for TB/HIV and TB Elimination, University of Brescia, Brescia, Italy. 4. Global TB Programme, WHO, Geneva, Switzerland. 5. Montreal Chest Institute, McGill University, Montreal, QC, Canada; Global TB Programme, WHO, Geneva, Switzerland. Electronic address: dick.menzies@mcgill.ca.
Abstract
BACKGROUND: WHO estimates that a third of the world's population has latent tuberculosis infection and that less than 5% of those infected are diagnosed and treated to prevent tuberculosis. We aimed to systematically review studies that report the steps from initial tuberculosis screening through to treatment for latent tuberculosis infection, which we call the latent tuberculosis cascade of care. We specifically aimed to assess the number of people lost at each stage of the cascade. METHODS: We did a systematic review and meta-analysis of study-level observational data. We searched MEDLINE (via OVID), Embase, and Health Star for observational studies, published between 1946 and April 12, 2015, that reported primary data for diagnosis and treatment of latent tuberculosis infection. We did meta-analyses using random and fixed effects analyses to identify percentages of patients with latent tuberculosis infection completing each step in the cascade. We also estimated pooled proportions in subgroups stratified by different characteristics of interest to assess risk factors for losses. RESULTS: We identified 58 studies, describing 70 distinct cohorts and 748 572 people. Steps in the cascade associated with greater losses included completion of testing (71·9% [95% CI 71·8-72·0] of people intended for screening), completion of medical evaluation (43·7% [42·5-44·9]), recommendation for treatment (35·0% [33·8-36·4]), and completion of treatment if started (18·8% [16·3-19·7]). Steps with fewer losses included receiving test results, referral for evaluation if test positive, and accepting to start therapy if recommended. Factors associated with fewer losses were immune-compromising medical indications, being part of contact investigations, and use of rifamycin-based regimens. INTERPRETATION: We identify major losses at several steps in the cascade of care for latent tuberculosis infection. Improvements in management of latent tuberculosis will need programmatic approaches to address the losses at each step in the cascade. FUNDERS: Canadian Institutes of Health Research.
BACKGROUND: WHO estimates that a third of the world's population has latent tuberculosis infection and that less than 5% of those infected are diagnosed and treated to prevent tuberculosis. We aimed to systematically review studies that report the steps from initial tuberculosis screening through to treatment for latent tuberculosis infection, which we call the latent tuberculosis cascade of care. We specifically aimed to assess the number of people lost at each stage of the cascade. METHODS: We did a systematic review and meta-analysis of study-level observational data. We searched MEDLINE (via OVID), Embase, and Health Star for observational studies, published between 1946 and April 12, 2015, that reported primary data for diagnosis and treatment of latent tuberculosis infection. We did meta-analyses using random and fixed effects analyses to identify percentages of patients with latent tuberculosis infection completing each step in the cascade. We also estimated pooled proportions in subgroups stratified by different characteristics of interest to assess risk factors for losses. RESULTS: We identified 58 studies, describing 70 distinct cohorts and 748 572 people. Steps in the cascade associated with greater losses included completion of testing (71·9% [95% CI 71·8-72·0] of people intended for screening), completion of medical evaluation (43·7% [42·5-44·9]), recommendation for treatment (35·0% [33·8-36·4]), and completion of treatment if started (18·8% [16·3-19·7]). Steps with fewer losses included receiving test results, referral for evaluation if test positive, and accepting to start therapy if recommended. Factors associated with fewer losses were immune-compromising medical indications, being part of contact investigations, and use of rifamycin-based regimens. INTERPRETATION: We identify major losses at several steps in the cascade of care for latent tuberculosis infection. Improvements in management of latent tuberculosis will need programmatic approaches to address the losses at each step in the cascade. FUNDERS: Canadian Institutes of Health Research.
Authors: Lisa A Ronald; Jonathon R Campbell; Caren Rose; Robert Balshaw; Kamila Romanowski; David Z Roth; Fawziah Marra; Kevin Schwartzman; Victoria J Cook; James C Johnston Journal: Clin Infect Dis Date: 2019-11-27 Impact factor: 9.079
Authors: Juan Manuel Cubillos-Angulo; María B Arriaga; Elisângela C Silva; Beatriz L A Müller; Daniela M P Ramalho; Kiyoshi F Fukutani; Pryscila F C Miranda; Adriana S R Moreira; Antonio Ruffino-Netto; Jose R Lapa E Silva; Timothy R Sterling; Afrânio L Kritski; Martha M Oliveira; Bruno B Andrade Journal: Clin Infect Dis Date: 2019-08-30 Impact factor: 9.079
Authors: Pierre J Plourde; Christopher A Basham; Shelley Derksen; Jennifer Schultz; Scott McCulloch; Linda Larcombe; Kathi Avery Kinew; Lisa M Lix Journal: Can J Public Health Date: 2019-07-11
Authors: Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar; Rishi K Gupta; Claire J Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C Aichelburg; Neus Altet; Roland Diel; Claudia C Dobler; Jose Dominguez; Joseph S Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M Hauri; Thomas Hermansen; James C Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W Aldridge; Andrew Copas; Molebogeng X Rangaka Journal: Nat Med Date: 2020-10-19 Impact factor: 53.440
Authors: Khai Hoan Tram; Florence Mwangwa; Gabriel Chamie; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Vivek Jain; Tamara D Clark; Dalsone Kwarisiima; Maya L Petersen; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Carina Marquez Journal: AIDS Care Date: 2019-06-10
Authors: Robert Belknap; David Holland; Pei-Jean Feng; Joan-Pau Millet; Joan A Caylà; Neil A Martinson; Alicia Wright; Michael P Chen; Ruth N Moro; Nigel A Scott; Bert Arevalo; José M Miró; Margarita E Villarino; Marc Weiner; Andrey S Borisov Journal: Ann Intern Med Date: 2017-11-07 Impact factor: 25.391